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Abstract: Imiquimod, an immune-modulating imidazoquinoline compound, has been approved 
in topical formulation for the treatment of actinic keratoses, superficial basal cell carcinomas, 
and external genital warts. Its use in the treatment of field cancerization, in particular, has been 
rapidly evolving. With the recent approval of a new drug application for a new concentration, 
as well as generic formulations, this drug has emerged at the forefront of treatment for actinic 
keratoses, with improved dosage scheduling and more patients having access to generic options. 
In the nearly 15 years since its original approval by the Food and Drug Administration for 
the treatment of actinic keratoses in 1997, topical imiquimod has been reviewed and studied 
extensively, not only for its safety and efficacy, but also for its tolerability in patients. This paper 
provides an indepth review of the literature, and provides clinical evidence for its inclusion in 
the arsenal of treatment options for patients with actinic keratoses.
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Introduction
Actinic keratoses are small, scaly, sandpaper-like papules found on sun-exposed areas 
of skin including the face, balding scalp, and arms. With an approximate four-year 
risk of evolving into basal cell carcinoma or squamous cell carcinoma of 1.6% and 
2.6%, respectively, these lesions are considered to be premalignant.1,2 There are many 
treatment options currently available for the treatment of actinic keratoses, including 
imiquimod, cryotherapy, 5-fluorouracil, 3% diclofenac in 2.5% hyaluronan gel, and 
topical photodynamic therapy, as well as new emerging potential therapies, such as 
ingenol-3-angelate. This review focuses on topical imiquimod and its history as a 
topical immune response modifier in the treatment of actinic keratoses.
Imiquimod, an imidazoquinoline compound, is a low molecular weight immune 
modifier which upregulates interferon-alpha, tumor necrosis factor-alpha, interleukin 
(IL)-1, IL-6, IL-8, IL-12, and other cytokines locally. It is capable of inducing both 
the innate and the adaptive immune responses in order to achieve enhancement of 
the endogenous immune response, and also upregulates the natural antitumor and 
antiviral cell response. In 1997, the Food and Drug Administration (FDA) approved 
topical imiquimod cream at a concentration of 5% to be used for the treatment of 
typical, nonhyperkeratotic, and nonhypertrophic actinic keratoses on the face or 
scalp in immunocompetent adults. In 2010, the FDA approved a 3.75% imiquimod 
formulation for treatment of clinical typical, visible, or palpable actinic keratoses on 
the face or balding scalp. Formulations, indications, and the dosing regimen are listed 
in Table 1. As new formulations and treatment regimens are approved, more data Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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will emerge on the safety and efficacy of topical imiquimod. 
Furthermore, we will gain more insight into its tolerability 
for patients.
Overview of imiquimod
Mechanism
Structurally, the chemical nomenclature of imiquimod is 
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine 
(Figure 1).3 Imiquimod acts as an immune modifier by 
targeting cytokine-producing cells, such as monocytes, mac-
rophages, and dendritic cells bearing toll-like receptor 7/8.4 
This first drug of its class acts via innate and acquired 
immune pathways in order to stimulate release of cytokines, 
such as tumor necrosis factor-alpha, IL-6, IL-12, and 
interferon-alpha, as well as activation of natural killer cells, 
antigen-presenting cells, T cells, and B cells (Figure 2). This 
cascade also results in the production of interferon-gamma 
by Th1 cells.5 Imiquimod induces cellular memory via the 
activation of effector T cells, Langerhans cells, lymphocytes, 
and macrophages, which circulate lymphatically and activate 
the adaptive immune response.
Metabolism and pharmacokinetics
When applied topically, the half-life of imiquimod is approxi-
mately 30 hours.6 Systemic absorption of imiquimod is 
minimal when the cream is applied to intact skin, with 97% 
of the drug recovered from the dosing site in one study. Other 
studies have demonstrated no quantifiable metabolites in 
serum, with ,0.9% of a single 5 mg dose excreted in urine 
and feces.7 There is no detectable radioactivity in serum. Kulp 
et al characterized serum markers in 19 subjects applying two 
packets (18.75 mg total) of imiquimod cream 3.75% once 
daily for 21 days to an area of skin on the face or balding 
scalp totaling approximately 200 cm2.8 After 21 days, the 
average maximum serum concentration was 0.323 mg/mL, 
with a half-life of 29 hours. Researchers concluded that 
systemic exposure of imiquimod was low after 21 days of 
application.
Differences in the release rates of imiquimod between the 
generic and brand formulations have been studied in vitro. 
Due to differences in the compositions of the vehicle creams, 
there may be differences in the safety and efficacy of generic 
versus brand medications as well. To answer this question, 
a nationwide, multicenter, double-blind, 16-week study is 
underway to compare vehicles used in the generic and brand 
formulations of imiquimod cream 5% for the treatment of 
actinic keratoses on the face or scalp.9
Safety
Due to the lack of data in animal models, the use of imi-
quimod is contraindicated during pregnancy. Imiquimod is 
listed as a Category C drug. Female patients of child-bearing 
age should be counseled regarding the importance of con-
traception before being prescribed imiquimod because its 
teratogenicity is as yet undetermined.
Clinical data
A double-blind, vehicle-controlled pilot study by Edwards 
el al evaluated imiquimod cream 5% versus vehicle in 
40   subjects with at least three actinic keratoses.10 When treated 
Table 1 Imiquimod formulations, indications, and dosing regimens
Imiquimod formulation Indication Dosing regimen
5% cream, topical Treatment of clinically typical, nonhyperkeratotic,  
nonhypertrophic actinic keratoses on the face or  
scalp in immunocompetent adults; restricted to an area  
of skin totaling 25 cm2
2 times per week for up to 16 weeks
3.75% cream, topical Treatment of clinically typical, visible, or  
palpable actinic keratoses on the full face or  
balding scalp
Daily use for 2 weeks, followed by 2 weeks of   
nontreatment, followed by 2 weeks of daily  
use for a total of 6 weeks
NH2
N
N
N
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three times per week for up to 16 weeks, 75% of lesions 
cleared, compared with 12% in the vehicle group. Some of 
the first reported cases of imiquimod 5% cream for the treat-
ment of actinic keratoses were by Stockfleth et al in 2001.11 
Six patients who had up to 10 actinic keratoses were treated 
2–3 times per week for 6–8 weeks, with complete clearance 
and no recurrences one year later. Persaud et al conducted a 
study of 22 patients, each acting as their own control, applying 
topical imiquimod 5% to one side of the body and vehicle to 
the other.12 At the end of eight weeks, a significant reduction in 
the number of lesions was observed for the imiquimod-treated 
side (from 10.1 to 6.2) compared with vehicle (8.1 to 7.6). An 
open-label trial of imiquimod 5% cream was conducted by 
Salasche et al, involving 25 patients with 5–20 discrete actinic 
keratoses, treated three times per week for four weeks, followed 
by a rest period of four weeks.13 If any lesions remained, patients 
repeated the eight-week cycle up to a maximum of 24 weeks. 
Researchers noted that although 45.5% of sites were clear by 
the end of the first cycle, actinic keratoses continued to clear 
during the “therapeutic interval” rest period. Complete clearing 
was achieved in 82% of lesions, including subclinical lesions 
that were uncovered by treatment with imiquimod. This cycling 
approach was able to achieve high efficacy while minimizing 
adverse effects.
Two multicenter, randomized, double-blind, parallel-
group, vehicle-controlled Phase III trials were conducted to 
evaluate the efficacy of imiquimod 5% cream for the treatment 
of actinic keratoses on the face and balding scalp.14 In total, 
436 patients were randomized to apply either   imiquimod 5% 
cream or vehicle once a day two times per week for 16 weeks. 
Complete clearance rates were 45.1% for the imiquimod 
group and 3.2% for the vehicle group. Although 17.7% of 
imiquimod-treated subjects reported severe erythema, only 
3% discontinued the study due to adverse events. The second 
Phase III study involved application of imiquimod 5% or 
vehicle cream once a day three times per week for 16 weeks 
in 286 patients.15 Histology-proven complete clearance rates 
were observed in 57.1% of imiquimod-treated and 2.2% of 
vehicle-treated subjects, with dropout rates due to adverse 
events of 4% and 3%, respectively.
Another pair of similar Phase III trials evaluated 492 
patients randomized to apply either imiquimod 5% cream 
or vehicle three times a week for 16 weeks.16 At eight weeks 
post-treatment, imiquimod-treated patients experienced 
an 86.6% reduction in the number of baseline lesions as 
compared with 14.3% for vehicle-treated patients. Long-term 
follow-up studies (1–2 years post-treatment) have shown 
continued clinical benefit of imiquimod treatment for actinic 
keratoses, with the majority of treated patients remaining 
clear, and low rates of recurrence.17
A meta-analysis comparing the efficacy of imiquimod 
5% cream versus 5-fluorouracil for the treatment of actinic 
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keratoses on the face and scalp concluded that imiquimod was 
more efficacious than 5-fluorouracil (70% ± 12%   versus 52% 
± 18%, respectively).18 Tanghetti and Werschler conducted 
a trial assessing 39 patients randomized to receive either 
5-  fluorouracil twice daily or imiquimod 5% twice weekly 
for treatment of actinic keratoses for 16 weeks.19 At the end 
of the study at week 24, reduction in the total actinic kera-
tosis count was 94% for 5-fluorouracil compared with 66% 
for imiquimod. However, more recent studies have reported 
sustained field clearance rates in all patients one year after 
treatment. In 75 patients treated with imiquimod 5% three 
times weekly for four weeks, 5-fluorouracil twice daily for 
four weeks or cryotherapy (including also those not cleared 
at the end of therapy), sustained clearance was achieved in 
73%, 33%, and 4% of patients, respectively.20
Stockfleth et al evaluated the response to a shortened 
course of treatment.21 In an open-label Phase IIIb trial, 
829 subjects applied imiquimod 5% cream or vehicle to the 
treatment area three times weekly for four weeks, followed 
by a four-week period of no treatment. If actinic keratoses 
remained, then a second four-week course of treatment was 
initiated. Complete and partial ($75% lesion   reduction) 
clearance rates were 68.9% and 80.2%, respectively, 
  similar to those observed after 16-week treatment courses. 
To investigate whether a lower concentration of imiquimod 
might be efficacious in the treatment of actinic keratoses with 
reduced adverse reactions, two placebo-controlled studies 
were performed comparing imiquimod 2.5% and 3.75% to the 
face or balding scalp for two-week or three-week cycles.22,23 
Results were similar for the two trials. In the two-week cycle 
study (daily treatment for two weeks, two weeks of no treat-
ment, followed by another two weeks of daily treatment), 
mean reductions from baseline lesion count were 25% for 
placebo, 72% for imiquimod 2.5%, and 82% for imiquimod 
3.75%.22 Furthermore, the sustained clearance of lesions in 
these patients remained significant at one-year follow-up, 
with 33% of imiquimod 2.5% subjects and 41% of imiquimod 
3.75% subjects remaining 100% clear of lesions.
When used in combination with cryotherapy, imiquimod 
has the ability to increase clearance of lesions. In a study 
of 63 subjects, when imiquimod 5% cream was used 
post-cryotherapy, a significantly greater total number of 
actinic keratoses were cleared compared with vehicle 
(23% versus 9%).24 Imiquimod cream 3.75% was also 
evaluated post-cryotherapy in a multicenter, double-blind, 
vehicle-controlled study.25 Patients with at least five actinic 
keratoses on the face were treated with cryotherapy, 
leaving at least five lesions untreated. One to two weeks 
post-cryotherapy, imiquimod 3.75% or vehicle cream 
was applied to the treatment area in two-week cycles as 
described previously. Complete clearance rates were 30% 
for imiquimod versus 3% for vehicle, with mean total lesion 
reductions of 87% versus 50%, respectively.
To assess field-directed therapies used in combination, the 
sequential use of photodynamic therapy with aminolevulinic 
acid followed by imiquimod was performed in 25 subjects 
with facial actinic keratoses.26 One month after photodynamic 
therapy, imiquimod or vehicle was applied to the area twice 
weekly for 16 weeks. At one year of follow-up, median lesion 
reduction was 90% for imiquimod versus 75% for vehicle, 
with no subject discontinuing due to an adverse event.
Nonmelanoma skin cancer affects a disproportionately 
large number of immunosuppressed patients. Ulrich et al 
reported five of six organ transplant recipients being 
successfully treated for actinic keratoses with topical 
imiquimod 5% cream.27 In this nonrandomized pilot study, 
imiquimod 5% was applied 2–3 times per week for 12–16 
weeks, with complete clearance of all lesions in five of 
six patients. Another study assessed graft function in 24 
transplant patients receiving treatment with imiquimod, 
finding that it was not altered, and that therapy was well 
tolerated.28 A larger, multicenter, randomized, placebo-
controlled study was undertaken by Ulrich et al involving 
43 transplant patients with actinic keratoses.29 Patients 
applied imiquimod 5% cream or vehicle three times per week 
for 16 weeks to a defined treatment area of 100 cm.2 Efficacy 
was similar to that in immunocompetent patients, with no 
patients experiencing transplant rejection or discontinuing 
due to drug-related adverse events.
Patient acceptability
Due to the ease, convenience, privacy, and autonomy asso-
ciated with self-administration, treatment of   dermatologic 
conditions with imiquimod cream is preferred by patients 
over physician-administered modalities.30 Patient preference 
should guide treatment, because clearance rates are 
  significantly enhanced with good patient compliance with 
any treatment regimen.
Patient preferences comparing imiquimod 5% and 
3.75% have not been formally surveyed to date. However, 
the reduced total treatment time for the 3.75% cream from 
16 weeks to six weeks offers a distinct advantage over the 5% 
cream in terms of patient compliance. Patients must still be 
made aware of the importance of prevention, sun avoidance, 
frequent skin examinations by a dermatologist, as well as the 
use of sun-protective outerwear and sun block.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Adverse effects
The most common adverse effect from topically applied imi-
quimod cream is a localized skin reaction at the application 
site. Generally, imiquimod is well accepted, with few patients 
choosing to discontinue therapy or withdrawal from clinical 
trials due to intolerable side effects.   Commonly, patients 
experience mild to moderate discomfort, with erythema, 
itching, burning, pain, edema, ulceration, and induration being 
reported most often. The erythema is characteristic of the local 
immune response, as imiquimod unmasks subclinical lesions 
and treats them in the process. A positive   correlation exists 
between histologic clearance rates for actinic keratoses and 
the severity of erythema, crusting, scabbing, and erosion.31 
Figure 3 provides an example of a characteristic patient 
response during a course of imiquimod therapy.
Rarely, imiquimod can trigger or exacerbate existing 
inflammatory conditions. Cases of arthritis,32 pemphigus 
foliaceous,33 psoriasis,34 actinic cheilitis,35 pityriasis rubra 
pilaris,36 alopecia,37 erosive pustular dermatosis of the 
scalp,38 and subacute cutaneous lupus erythematosus39 
attributed to treatment with imiquimod have been alleged 
in the literature.
Cost analysis
A pharmacoeconomic analysis of the treatment of actinic 
keratosis found that although imiquimod is the initially more 
expensive of the medications approved by the FDA, when 
treating multiple lesions, it offers an advantage over cryo-
therapy or photodynamic therapy with 5-aminolevulinic acid 
in that patients do not need to return over multiple days for 
in-office treatment, thus reducing the cost to the patient.40
Studies have demonstrated a low incidence of new actinic 
keratotic lesions after treatment with imiquimod, due to its abil-
ity to induce immunologic memory.41 This long-term clearance 
offers an advantage in terms of the cost of retreating areas of 
recurrence. By treating the field of cancerization, subclinical 
lesions are eradicated, thus eliminating the need to wait until 
these lesions are clinically visible and further progressed.
Conclusion
Topical imiquimod has proven to be safe and efficacious in 
the treatment of actinic keratoses, with tolerable transient local 
adverse effects. The ability of imiquimod to elicit an immune 
response and to treat subclinical lesions makes it among the 
most strategic therapies for these patients. With the availability 
of two concentrations, as well as generic formulations, 
imiquimod cream will no doubt continue to be used as effective 
monotherapy for patients with field cancerization in larger 
exposed skin areas. The research reviewed here highlights over 
a decade of clinical data on topical imiquimod. Field-directed 
therapies for the treatment of actinic keratoses will continue 
to emerge in this rapidly evolving field. Although no topical 
therapy has 100% efficacy without recurrence, imiquimod is 
among the forefront of these therapies, with much evidence-
based justification for its place in the dermatologist’s arsenal.
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